{'fraction_non_alphanumeric': 0.0219435736677116, 'fraction_numerical': 0.006269592476489028, 'mean_word_length': 6.430232558139535, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dexmedetomidine versus midazolam for conscious sedation in endoscopic retrograde cholangiopancreatography: An open-label randomised controlled trial

In the open‐label randomised controlled trial on dexmedetomidine versus midazolam for conscious sedation published in Indian Journal of Anaesthesia, Sethi et al. have concluded that dexmedetomidine can be a superior alternative to midazolam for conscious sedation in endoscopic retrograde cholangiopancreatography (ERCP) based on early recovery, better patient and endoscopist satisfaction score, less complication and better Facial Pain Scale (FPS) score at 5 and 10 min of procedure.[1]